Board of Managers
Chairman of the Board
Bill Moffitt has 40 years of experience in the diagnostics and medical device industry and has spent the last 20 years developing novel technologies into products and solutions that have helped shape the industry. Moffitt was President, Chief Executive Officer and a director of Nanosphere, Inc., a nanotechnology-based molecular diagnostic company. Previously, he served as President and CEO of i-STAT Corporation, a developer, manufacturer and marketer of diagnostic products that pioneered the point-of-care blood analysis market. Moffitt led i-STAT from its early research stage to commercialization and the creation of strategic alliances with Hewlett Packard and Abbott Labs and ultimately to its initial public offering and acquisition by Abbott in 2003. Moffitt also held increasingly responsible executive positions with Baxter Healthcare Corporation and American Hospital Supply Corporation. He is a director of several private companies in the life sciences industry. Moffitt earned a B.S. in Zoology (minor in chemistry) from Duke University.
Josep Manent has over 35 years of business, financial, product development and marketing experience in the in vitro diagnostics (IVD) industry. Manent held senior management positions in the Werfen Life Group, a family of leading companies in the IVD sector including CEO of Instrumentation Laboratory, a leader in critical care, hemostasis and point-of-care diagnostics, from 1999 to 2011. As CEO of IL Manent helped return the company to profitability and become a world leader in hemostasis and point-of-care through a combination of creative customer targeting, efficient manufacturing and a focus on innovative product development. Prior to serving as CEO, Manent was IL’s Senior Vice President of Corporate Development from 1991 to 1999. Prior to that Manent was a co-founder of Biokit, a developer of systems and immunoassays for clinical laboratories, and President and General Manager for 20 years. Biokit was acquired by Werfen. Manent received his MBA at ESADE Business School and participated at Executive and Marketing programs at Stanford University.
President and Chief Executive Officer
Timothy Fischer has been a pioneer in the in vitro diagnostics industry in the fields of hematology, oncology and pathology for the past 25 years. He has led the design, development and commercialization of dozens of novel diagnostic products. He holds over 40 patents and has authored numerous publications. Prior to joining HemoSonics, Fischer served as Chief Operating Officer for LipoScience, a publically traded in-vitro diagnostics company, where he led the successful development of the Vantera® Clinical Analyzer from concept through development, regulatory approval and market adoption. Previously, he served as Vice President of Development for the Women’s Health and Cancer business unit at Becton Dickinson and as the Vice President of Product Development for TriPath Oncology. Fischer holds a Bachelor of Science degree in Biology from Indiana University.
Founder and Chief Technology Officer
William Walker, PhD, has 25 years of experience in the development of medical ultrasound technology, with expertise in instrumentation, ultrasound physics, clinical applications, intellectual property and market assessment. He has been an active founder in three ultrasound-based medical device companies. Walker applied his entrepreneurial temperament as a faculty member at the University of Virginia from 1997 to 2010. He has a proven ability to build and motivate world-class technology development teams, garner the resources to support them, and achieve dramatic breakthroughs. Walker holds both BSE and PhD degrees in Biomedical Engineering from Duke University. Walker currently splits his time between HemoSonics and Duke University, where he is Director of Engineering Entrepreneurial Ventures.
Founder and Chief Scientific Officer
Francesco Viola, PhD, has more than 10 years of experience in the area of medical ultrasound imaging, advanced signal processing and development of medical instrumentation. Viola has published his research in numerous engineering and biomedical peer-reviewed journals and he is the co-inventor in a number of patents in the field of ultrasound imaging and sensing. He is also the first recipient of The Emerging Technologies and Healthcare Innovations Congress (TETHIC) Award for achievements in scholarship and contributions to healthcare technology translation. Viola holds a Laurea in Biomedical Engineering from the Polytechnic University of Milan, Italy, and a PhD in Biomedical Engineering from the University of Virginia.
Mark Wheeler, MD, is a retired physician with 25 years experience in medical investments. He has authored a biotechnology newsletter for high-net-worth individuals and participated in the creation of numerous start-ups in both the pharmaceutical and medical device arenas. He founded WT Investment Advisors LP in 2003, which has holdings in privately held American biotechnology companies. Wheeler earned his medical degree from Wake Forest University and his undergraduate degree from Princeton University.
- Anesthesia & Analgesia Profiles Quantra’s SEER Technology in Article of the Month and Podcast
- Abstract on SEER Technology to be Presented at PGA
- HemoSonics’ Groundbreaking System for the Management of Critical Bleeding Presented in Four Articles in Anesthesia & Analgesia
- Introduction to Quantra™ Published in Anesthesia and Analgesia